Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2026)

Harmony Biosciences Holdings has reported Share-based Compensation for 8 years, with the latest figure at $33.8 million in Q1 2026.

• Quarterly Share-based Compensation rose 170.17% year-over-year to $33.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.8 million (up 783.31% YoY) and the FY2025 annual result came in at $44.9 million, up 186.72% from the prior year.
• Share-based Compensation slipped to $33.8 million in Q1 2026 per HRMY's latest filing, from $42.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $59.8 million in Q3 2024 and troughed at -$30.0 million in Q4 2024.
• A 5-year average of $14.8 million and a median of $9.2 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 651.53% in 2024, then slumped 61.97% in 2025.
• Over 5 years, Share-based Compensation stood at $6.9 million in 2022, then rose by 14.67% to $8.0 million in 2023, then plunged by 477.44% to -$30.0 million in 2024, then jumped by 241.69% to $42.6 million in 2025, then fell by 20.64% to $33.8 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $33.8 million, $42.6 million, and $22.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.